Budesonide and ambroxol hydrochloride in the treatment of mycoplasma pneumoniae pneumonia in children
布地奈德与盐酸氨溴索治疗小儿支原体肺炎

摘要

目的 探讨布地奈德与盐酸氨溴索联合应用在治疗小儿支原体肺炎中的疗效。方法 2023年2月至2024年2月，选取小儿支原体肺炎患儿50例参与研究，随机分成两组：对照组25人，接受单独布地奈德治疗；观察组25人，接受布地奈德与盐酸氨溴索联合治疗。对比两组治疗效果。结果 治疗后，观察组症状改善时间、肺功能指标均优于对照组，有统计学意义（P＜0.05）。结论 布地奈德与盐酸氨溴索联合治疗小儿支原体肺炎能显著改善患儿临床症状，有效改善肺功能指标，值得临床推广应用。

Abstract

Objective To explore the efficacy of the combination of budesonide and ambroxol hydrochloride in the treatment of Mycoplasma pneumoniae pneumonia in children.
Methods From February 2023 to February 2024, 50 children with Mycoplasma pneumoniae pneumonia were selected to participate in the study and randomly divided into two groups: a control group of 25 people who received treatment with budesonide alone; Observation group of 25 people received combined treatment with budesonide and ambroxol hydrochloride. Compare the therapeutic effects of two groups.
Results treatment, the observation group showed better symptom improvement time and lung function indicators than the control group, with statistical significance (P<0.05).
Conclusion   The combination therapy of budesonide and ambroxol hydrochloride can significantly improve the clinical symptoms of children with mycoplasma pneumonia, effectively improve lung function indicators, and is worthy of clinical promotion and application.